Treats active duodenal ulcer. ANDA 90576, held by Amneal Pharms. Nizatidine.
As of Nov 16, 2026, ANDA 90576 (Nizatidine), held by Amneal Pharms, was first approved by FDA on Nov 18, 2009, with 0 approved supplements and 0 published complete response letters.
Indications and Usage: Nizatidine oral solution is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine oral solution is indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine oral solution is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine oral solution is
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 2009 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nizatidine15MG/ML · solution;oral | Nizatidine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters